Buy Reta-Cagri 5mg/5mg
Retatrutide + Cagrilintide dual agonist blend for next-generation obesity management
Reta-Cagri 5mg/5mg For Sale — Reta-Cagri combines Retatrutide (GIP/GLP-1/glucagon triple agonist) with Cagrilintide (long-acting amylin analog) — representing the next generation of obesity pharmacology beyond semaglutide.
- Retatrutide's 24% body weight loss in Phase II (highest ever reported)
- Cagrilintide's amylin mechanism is complementary to GLP-1 action
- Four receptors targeted simultaneously: GIP, GLP-1, glucagon, amylin
- Next-generation beyond semaglutide in development pipeline
- Amylin pathway reduces glucagon and enhances satiety signals
COA verified · US domestic shipping
Reta-Cagri: Combining Retatrutide Triple Agonism with Cagrilintide Amylin Action for Maximum Weight Loss
24% Body Weight Loss
Retatrutide's Phase II trial produced 24% body weight reduction over 48 weeks — the highest weight loss ever reported for any injectable obesity medication in clinical history.
Four-Receptor Mechanism
GIP + GLP-1 + Glucagon + Amylin receptor activation simultaneously — an unprecedented mechanistic breadth targeting appetite, energy expenditure, hepatic fat, and satiety through four independent pathways.
CagriSema Validation
Cagrilintide + semaglutide (CagriSema) showed 22.7% vs 16.1% weight loss for semaglutide alone in Phase III — confirming the additive amylin benefit and validating the multi-mechanism approach.
Next Generation Pipeline
Both compounds are in active Phase III development, representing the next tier of approved obesity pharmacology expected to surpass semaglutide — Reta-Cagri provides research access to both simultaneously.
The Science Behind Reta-Cagri 5mg/5mg
▸The Next Generation of Obesity Pharmacology
Reta-Cagri combines two of the most advanced obesity pipeline compounds into a single formulation: Retatrutide (LY3437943), Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist currently in Phase III, and Cagrilintide, Novo Nordisk's long-acting amylin analog that is the companion drug to semaglutide in the Phase III CagriSema combination trial. This combination targets four complementary weight loss mechanisms simultaneously.
▸Retatrutide: Triple Receptor Agonism
Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously — building on semaglutide's dual GLP-1 mechanism by adding GIP (the incretin hormone that enhances GLP-1's effects and reduces GI side effects) and glucagon (which drives hepatic fat oxidation and thermogenesis). Phase II data showed 24% body weight loss over 48 weeks — the highest weight loss reported for any injectable obesity drug in clinical trials.
▸Cagrilintide: Amylin Pathway
Cagrilintide is a long-acting amylin analog that activates amylin receptors in the hypothalamus and brainstem to reduce caloric intake through a mechanism completely distinct from GLP-1. Amylin suppresses glucagon, slows gastric emptying, and directly activates satiety neurons. Combined with semaglutide in the CagriSema trial, cagrilintide + semaglutide showed 22.7% body weight loss versus 16.1% for semaglutide alone — confirming the additive benefit of amylin pathway targeting.
Complete Reta-Cagri 5mg/5mg Benefits
- Retatrutide's 24% body weight loss in Phase II (highest ever reported)
- Cagrilintide's amylin mechanism is complementary to GLP-1 action
- Four receptors targeted simultaneously: GIP, GLP-1, glucagon, amylin
- Next-generation beyond semaglutide in development pipeline
- Amylin pathway reduces glucagon and enhances satiety signals
- Triple agonism + amylin may synergistically exceed any single mechanism
- Targets both appetite and energy expenditure through multiple pathways
Reta-Cagri 5mg/5mg Dosing Protocol
Reconstitution: Add 2mL bacteriostatic water (Reta: 2,500mcg/mL + Cagri: 2,500mcg/mL).
Dosing:
• Research: start at 0.25mg each weekly, escalate monthly
• Retatrutide clinical: 0.5–12mg weekly escalation over 12 weeks
• Cagrilintide clinical: 0.25–4.5mg weekly escalation
Note: Advanced pipeline compounds; base protocols on Phase II/III clinical data
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
Reta-Cagri 5mg/5mg
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Stack Reta-Cagri 5mg/5mg With
Weight Loss5-Amino-1MQ 50mg
NNMT inhibitor for fat cell reduction, NAD+ elevation, and metabolic enhancement
Buy 5-Amino-1MQ 50mg — 5-Amino-1MQ is a selective NNMT inhibitor that reduces fat cell size, elevates intracellular NAD+, and enhances metabolic rate — the mechanistically novel small molecule for body composition.
Weight LossMazdutide 6mg
GLP-1/glucagon dual agonist for superior weight loss and metabolic control
Trusted Mazdutide 6mg — Mazdutide is a once-weekly GLP-1/glucagon receptor dual agonist in Phase III trials that produces superior weight loss versus GLP-1 monotherapy by adding thermogenic glucagon activation.
Weight LossSemaglutide 3mg
GLP-1 receptor agonist for appetite suppression, glucose control, and weight loss
Buy Semaglutide 3mg — Semaglutide 3mg — the GLP-1 receptor agonist behind Ozempic and Wegovy, for appetite suppression, blood glucose control, and significant body weight reduction.